For instance, it has been reported that EVO enhances chemosensitivity in CRC by targeting RRM2 [28] and inhibits CRC growth through RTKs-mediated PI3K/AKT/p53 signaling pathway [29]. This evidence concerns the gene AKT1 and colorectal carcinoma.